ClinicalTrials.gg
TerminatedNCT06700720Updated Sep 23, 2026

YN001-004 in Patients With Coronary Atherosclerosis in Australia

A Phase 2 interventional study of Dose 1 YN001 and Dose 2 YN001 in Coronary Artery Disease and Coronary Atherosclerotic Disease, sponsored by Beijing Inno Medicine Co., Ltd.. Terminated at 6 sites in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Beijing Inno Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated at the request of the Sponsor.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 89 studies in Coronary Artery Disease with a site in Australia — 11 open to participants now, 17 under way, 4 of them phase 3. Coronary Artery Disease · Australia.

Enrollment
81st of 82
3 · median 626
Started
2026
with 3 others
Phase 2
8 of 89
3 open now
Registered
85th of 89
by date

Among the 89 studies in Coronary Artery Disease with a site in Australia, this one is the 81st largest by enrollment of the 82 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 in phase 2, and was the 85th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

11 of the 89 studies in Coronary Artery Disease with a site in Australia are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Coronary Artery Disease with a site in Australia, or all of them as a file.
02

Study summary

This study is to evaluate the efficacy and safety of intravenously administered YN001 in patients with coronary atherosclerosis in Australia. This study will be conducted in eligible participants with a diagnosis of coronary atherosclerosis, and at least 1 coronary artery is blocked determined by coronary computed tomography angiography (CCTA)

Read the detailed description

This is a multicenter, randomized, open label, parallel-group, proof of concept study. It is designed to determine if the study drug, called YN001, administered in addition to evolocumab can effectively reduce the total amount of plaque formed in the coronary artery as measured by CCTA from baseline to week 13.

A total of 24 patients with coronary atherosclerosis are expected to be enrolled and will be randomly assigned in a 1:1 ratio to 1 of 2 YN001 treatment arms (12 patients per arm) with 2 different dose levels for 12 weeks.

The study will be comprised of a maximum 41-day screening period (Day -42-Day -2), a baseline period (Day-1), a treatment and observation period (W1D1- W13D7), and a safety follow-up period (14 days post last dose).

03

Conditions studied

  • Coronary Artery Disease
  • Coronary Atherosclerotic Disease

Keywords

  • Coronary Atherosclerosis
  • Plaque regression
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the purposes, features, and methods of the study, and sign the ICF before performing any assessment.
  2. Male or female Australia patients between 18 and 75 years.
  3. Patients diagnosed with coronary atherosclerosis, and at least 1 vessel with diameter stenosis determined by coronary computed tomography angiography (CTA).
  4. Female patients must be non-pregnant and non-lactating, and females of (including a female partner of a male patient) must agree to use 1 effective method from the screening period to 3 months after receiving their last dose of the study drug. In addition, male patients must be willing to refrain from sperm donation during this time.
  5. Willing and able to comply with the requirements of protocol to the best of the patient's and investigator's knowledge.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with other drug(s) within 30 days or 5 half-lives, whichever is longer, prior to randomization.
  2. Previously received YN001.
  3. Any type of vaccination within 4 weeks prior to randomization.
  4. for coronary CTA (e.g., known history of anaphylactic contrast reactions).
  5. Multi-vessel severe disease.
  6. Recent acute ST-segment elevation myocardial infarction (STEMI) occurred within 2 weeks prior to randomization.
  7. Relapse and highly symptomatic arrhythmia uncontrolled by drugs within the past 3 months, such as ventricular tachycardia, atrial fibrillation with rapid ventricular rate and paroxysmal supraventricular tachycardia.
  8. Prior treatment with CABG, heart transplantation, SAVR/TAVR, etc., or CABG, heart transplantation, SAVR/TAVR, etc., is required or planned during the study.
  9. PCI performed within 4 weeks prior to randomization or PCI is required or planned during study treatment.
  10. (NYHA) class III or IV, or last known (LVEF) \<40%.
  11. Recent clinically evident stroke occurred within 6 months prior to randomization (except for ).
  12. Presenting with history of myopathy/myalgia, or susceptible to myopathy/rhabdomyolysis.
  13. Known inflammatory bowel disease, ulcers, gastrointestinal or rectal bleeding within 6 months prior to randomization.
  14. Evidence of major diseases that not recovered within 2 weeks prior to randomization, or major surgery is expected during the study.
  15. Presenting with history of (except in patients who have been disease-free >5 years; or whose only malignancy has been basal or squamous cell skin carcinoma).
  16. Presence of any type of disease.
  17. Allergy to multiple food or drugs or known sensitivity to any components to be administered during dosing
  18. is less than 1 year.
  19. Systolic blood pressure of ≥150 mmHg at final screening despite antihypertensive therapy.
  20. Known familial hypercholesterolemia
  21. Triglycerides≥400 mg/dl (4.5 mmol/l) at final screening.
  22. Active liver disease or hepatic dysfunction defined by any of , AST, or total > 2 times (ULN) at final screening.
  23. Presence of renal insufficiency.
  24. Untreated or inadequately treated hypothyroidism defined by thyroid stimulating hormone (TSH) > 1.5 times ULN at final screening.
  25. Poorly controlled (defined by > 9%) type 2 diabetes mellitus.
  26. A positive surface antigen (HBsAg), or positive antibody against virus (anti-HCV) or (anti-HIV), or positive treponema pallidum antibody (TP-Ab).
  27. Current smoker who has smoked an average of≥5 cigarettes (or equivalent) per day over the preceding year.
  28. Presence of any other diseases or conditions (apart from those outlined above) that, in the opinion of the investigator, would make it unsuitable for the patient to participate in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Dose 1 treatment arm

    Dose 1 YN001 will be administrated intravenously weekly.

    Drug: Dose 1 YN001 · Drug: Evolocumab

  • Experimental
    Dose 2 treatment arm

    Dose 2 YN001 will be administrated intravenously weekly.

    Drug: Dose 2 YN001 · Drug: Evolocumab

Interventions

  • DrugDose 1 YN001

    Dose 1 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.

  • DrugDose 2 YN001

    Dose 2 YN001 will be administered on Day 1 of each week from Week 1 to Week 13, 13 times in total.

  • Evolocumab 140 mg will be administered subcutaneously every 2 weeks.

    Also known as: Repatha®

06

What researchers measure

Primary outcomes

  1. Changes in coronary plaque characteristics (volume and composition)

    Evaluating YN001 on top of evolocumab therapy in changing coronary plaque volume assessed by coronary computed tomography angiography (CCTA).

    Time frame: From baseline to Week 13

Secondary outcomes

  1. Change in mean of mean carotid IMT

    Evaluating YN001 on top of evolocumab therapy in changing carotid intima-media thickness (IMT) assessed by carotid ultrasound.

    Time frame: From baseline to Week 13

  2. Change in mean of mean carotid IMT

    Evaluating YN001 on top of evolocumab therapy in changing carotid intima-media thickness (IMT) assessed by carotid ultrasound.

    Time frame: From baseline to Week 5

  3. Change in mean of mean carotid IMT

    Evaluating YN001 on top of evolocumab therapy in changing carotid intima-media thickness (IMT) assessed by carotid ultrasound.

    Time frame: From baseline to Week 9

  4. Change in mean peri-coronary Fat attenuation index (FAI)

    Evaluating YN001 on top of evolocumab therapy in changing inflammation using the peri-coronary FAI value measured by quantitative CTA analysis.

    Time frame: From baseline to Week 13

  5. The safety profile of YN001

    Incidence of Adverse events (AEs)/Serious adverse events (SAEs)

    Time frame: From baseline to Week 15

  6. Plasma concentration of total and free drug

    Plasma concentration of total and free drug at pre-dose (0 h) and at the end of infusion

    Time frame: From Week 1 to Week 13

  7. Population pharmacokinetics (PK)

    Plasma PK parameter (AUC) and patient covariates of interest will be evaluated graphically and in the population PK model.

    Time frame: From Week 1 to Week 13

Other outcomes

  1. Immunogenicity(ADA) analysis

    The proportion of patients who develop anti-drug antibodies (ADA) following drug administration.

    Time frame: From Week 1 to Week 13

  2. Immunogenicity (APA)analysis

    The proportion of patients with pre-exsiting anti-PEG antibodies (APA), treatment emergent APA or treatment boosted APA following drug administration.

    Time frame: From screening to Week 13

  3. Exploratory dose-response analysis of plaque volume

    Exploratory dose-response analysis will be performed by comparing the difference of coronary plaque volume changing between 2 different dose levels

    Time frame: From Week 1 to Week 13

  4. Exploratory dose-response analysis of AEs

    Exploratory dose-response analysis will be performed by comparing the difference of incidence of AEs between 2 different dose levels

    Time frame: From Week 1 to Week 13

07

Study locations

6 sites
  • Canberra Hospital
    Canberra, Australian Capital Territory, Australia
  • Albury Wodonga Private Hospital
    Albury, New South Wales 1125, Australia
  • Sunshine Coast University Private Hospital
    Birtinya, Queensland 4575, Australia
  • Altona Clinical Research
    Melbourne, Victoria 3025, Australia
  • Peninsula Heart Centre
    Melbourne, Victoria 3199, Australia
  • John Flynn Private Hospital
    Tugun, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in Jul 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2024
First posted
Nov 22, 2024
StartActual
Feb 25, 2026
Primary completionActual
Jul 22, 2026
CompletionActual
Jul 22, 2026
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06700720
Lead sponsor
Beijing Inno Medicine Co., Ltd.
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Feb 25, 2026
Primary completion
Jul 22, 2026
Completion
Jul 22, 2026
Last update
Sep 23, 2026

Study contacts

Teresa Chen, PhD
study director · Beijing Inno Medicine Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion